Welcome!

News Feed Item

Status Epilepticus Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Status Epilepticus Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02280949/Status-Epilepticus-Global-Clinical-Trials-Review-H2-2014.html

Status Epilepticus Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Status Epilepticus Global Clinical Trials Review, H2, 2014" provides data on the Status Epilepticus clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Status Epilepticus. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Status Epilepticus. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Status Epilepticus 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Clinical Trials by G7 Countries: Proportion of Status Epilepticus to Central Nervous System Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Status Epilepticus to Central Nervous System Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Unaccomplished Trials of Status Epilepticus 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Status Epilepticus Therapeutics Clinical Trials 28
Prominent Drugs 29
Clinical Trial Profiles 30
Clinical Trial Overview of Top Companies 30
Sage Therapeutics 30
Clinical Trial Overview of Sage Therapeutics 30
Ligand Pharmaceuticals, Inc. 31
Clinical Trial Overview of Ligand Pharmaceuticals, Inc. 31
Mylan Inc. 32
Clinical Trial Overview of Mylan Inc. 32
Clinical Trial Overview of Top Institutes / Government 33
Assistance Publique - Hopitaux de Paris 33
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 33
Eunice Kennedy Shriver National Institute of Child Health and Human Development 34
Clinical Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human Development 34
Xuanwu Hospital Capital Medical University 35
Clinical Trial Overview of Xuanwu Hospital Capital Medical University 35
University of Malawi 36
Clinical Trial Overview of University of Malawi 36
Postgraduate Institute of Medical Education and Research 37
Clinical Trial Overview of Postgraduate Institute of Medical Education and Research 37
Shiraz University of Medical Sciences 38
Clinical Trial Overview of Shiraz University of Medical Sciences 38
University of Virginia 39
Clinical Trial Overview of University of Virginia 39
Hillel Yaffe Medical Center 40
Clinical Trial Overview of Hillel Yaffe Medical Center 40
All India Institute of Medical Sciences 41
Clinical Trial Overview of All India Institute of Medical Sciences 41
University of Michigan 42
Clinical Trial Overview of University of Michigan 42
Five Key Clinical Profiles 43
Appendix 67
Abbreviations 67
Definitions 67
Research Methodology 68
Secondary Research 68
About GlobalData 69
Contact Us 69
Disclaimer 69
Source 69

List of Tables

Status Epilepticus Therapeutics, Global, Clinical Trials by Region, 2014* 7
Status Epilepticus Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Status Epilepticus Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Status Epilepticus Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Status Epilepticus Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Status Epilepticus Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Status Epilepticus Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Proportion of Status Epilepticus to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Status Epilepticus Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Status Epilepticus Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 16
Proportion of Status Epilepticus to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 17
Status Epilepticus Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 18
Status Epilepticus Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 19
Status Epilepticus Therapeutics, Global, Clinical Trials by Phase, 2014* 20
Status Epilepticus Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 21
Status Epilepticus Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Status Epilepticus Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Status Epilepticus Therapeutics, Global, Withdrawn Clinical Trials, 2014* 24
Status Epilepticus Therapeutics, Global, Terminated Clinical Trials, 2014* 24
Status Epilepticus Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 25
Status Epilepticus Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 26
Status Epilepticus Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 27
Status Epilepticus Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 28
Status Epilepticus Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 29
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Sage Therapeutics, 2014* 30
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Ligand Pharmaceuticals, Inc., 2014* 31
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Mylan Inc., 2014* 32
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 33
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2014* 34
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Xuanwu Hospital Capital Medical University, 2014* 35
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Malawi, 2014* 36
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Postgraduate Institute of Medical Education and Research, 2014* 37
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Shiraz University of Medical Sciences, 2014* 38
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Virginia, 2014* 39
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by Hillel Yaffe Medical Center, 2014* 40
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by All India Institute of Medical Sciences, 2014* 41
Status Epilepticus Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Michigan, 2014* 42

List of Figures

Status Epilepticus Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Status Epilepticus Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Status Epilepticus Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Status Epilepticus Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 10
Status Epilepticus Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Status Epilepticus Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Status Epilepticus Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Proportion of Status Epilepticus to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 14
Status Epilepticus Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 15
Status Epilepticus Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 16
Proportion of Status Epilepticus to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 17
Status Epilepticus Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 18
Status Epilepticus Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 19
Status Epilepticus Therapeutics, Global, Clinical Trials by Phase (%), 2014* 20
Status Epilepticus Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 21
Status Epilepticus Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Status Epilepticus Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Status Epilepticus Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 25
Status Epilepticus Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 26
Status Epilepticus Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 27
Status Epilepticus Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 28
Status Epilepticus Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 29
GlobalData Methodology 68


To order this report: Status Epilepticus Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02280949/Status-Epilepticus-Global-Clinical-Trials-Review-H2-2014.html



__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., discussed how these tools can be leveraged to develop a lasting competitive advantage ...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web communications world. The 6th WebRTC Summit continues our tradition of delivering the latest and greatest presentations within the world of WebRTC. Topics include voice calling, video chat, P2P file sharing, and use cases that have already leveraged the power and convenience of WebRTC.
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes a lot of work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reduction in cost ...
Consumers increasingly expect their electronic "things" to be connected to smart phones, tablets and the Internet. When that thing happens to be a medical device, the risks and benefits of connectivity must be carefully weighed. Once the decision is made that connecting the device is beneficial, medical device manufacturers must design their products to maintain patient safety and prevent compromised personal health information in the face of cybersecurity threats. In his session at @ThingsExpo...
SYS-CON Events announced today that Massive Networks will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Massive Networks mission is simple. To help your business operate seamlessly with fast, reliable, and secure internet and network solutions. Improve your customer's experience with outstanding connections to your cloud.
DevOps is under attack because developers don’t want to mess with infrastructure. They will happily own their code into production, but want to use platforms instead of raw automation. That’s changing the landscape that we understand as DevOps with both architecture concepts (CloudNative) and process redefinition (SRE). Rob Hirschfeld’s recent work in Kubernetes operations has led to the conclusion that containers and related platforms have changed the way we should be thinking about DevOps and...
The question before companies today is not whether to become intelligent, it’s a question of how and how fast. The key is to adopt and deploy an intelligent application strategy while simultaneously preparing to scale that intelligence. In her session at 21st Cloud Expo, Sangeeta Chakraborty, Chief Customer Officer at Ayasdi, will provide a tactical framework to become a truly intelligent enterprise, including how to identify the right applications for AI, how to build a Center of Excellence to ...
From 2013, NTT Communications has been providing cPaaS service, SkyWay. Its customer’s expectations for leveraging WebRTC technology are not only typical real-time communication use cases such as Web conference, remote education, but also IoT use cases such as remote camera monitoring, smart-glass, and robotic. Because of this, NTT Communications has numerous IoT business use-cases that its customers are developing on top of PaaS. WebRTC will lead IoT businesses to be more innovative and address...
Everything run by electricity will eventually be connected to the Internet. Get ahead of the Internet of Things revolution and join Akvelon expert and IoT industry leader, Sergey Grebnov, in his session at @ThingsExpo, for an educational dive into the world of managing your home, workplace and all the devices they contain with the power of machine-based AI and intelligent Bot services for a completely streamlined experience.
Because IoT devices are deployed in mission-critical environments more than ever before, it’s increasingly imperative they be truly smart. IoT sensors simply stockpiling data isn’t useful. IoT must be artificially and naturally intelligent in order to provide more value In his session at @ThingsExpo, John Crupi, Vice President and Engineering System Architect at Greenwave Systems, will discuss how IoT artificial intelligence (AI) can be carried out via edge analytics and machine learning techn...
FinTechs use the cloud to operate at the speed and scale of digital financial activity, but are often hindered by the complexity of managing security and compliance in the cloud. In his session at 20th Cloud Expo, Sesh Murthy, co-founder and CTO of Cloud Raxak, showed how proactive and automated cloud security enables FinTechs to leverage the cloud to achieve their business goals. Through business-driven cloud security, FinTechs can speed time-to-market, diminish risk and costs, maintain continu...
SYS-CON Events announced today that GrapeUp, the leading provider of rapid product development at the speed of business, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Grape Up is a software company, specialized in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market acr...
Existing Big Data solutions are mainly focused on the discovery and analysis of data. The solutions are scalable and highly available but tedious when swapping in and swapping out occurs in disarray and thrashing takes place. The resolution for thrashing through machine learning algorithms and support nomenclature is through simple techniques. Organizations that have been collecting large customer data are increasingly seeing the need to use the data for swapping in and out and thrashing occurs ...